Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8738666 | International Journal of Antimicrobial Agents | 2018 | 24 Pages |
Abstract
To evaluate the activity of ceftolozane/tazobactam compared with other broad-spectrum antimicrobials against Pseudomonas aeruginosa and Enterobacteriaceae, 497 non-duplicate P. aeruginosa and 802 Enterobacteriaceae clinical isolates were consecutively collected during the period from September 2014 to April 2015 from patients in Germany with bloodstream, lower respiratory tract, intra-abdominal or urinary tract infections. Antimicrobial susceptibility testing was performed by broth microdilution. Results were interpreted according to EUCAST criteria. Ceftolozane/tazobactam showed good activity against Escherichia coli and Klebsiella pneumoniae isolates with MIC50/90 values of 0.25/0.5âmg/L and 0.25/1âmg/L, respectively. Comparatively, piperacillin/tazobactam, ceftazidime and meropenem MIC50/90 values were 2/8âmg/L, 0.25/8âmg/L and â¤0.03/ââ¤â0.03âmg/L, respectively, for E. coli, and 2/16âmg/L, 0.12/8âmg/L, and â¤0.03/ââ¤â0.03âmg/L, respectively, for K. pneumoniae isolates. The activity of ceftolozane/tazobactam against P. aeruginosa was superior to that of other antipseudomonal antimicrobials. Based on MIC50/90 values, ceftolozane/tazobactam (0.5/2âmg/L) was more active than piperacillin/tazobactam (8/64âmg/L), ceftazidime (2/16âmg/L), cefepime (2/16âmg/L) or meropenem (0.5/8âmg/L). In conclusion, ceftolozane/tazobactam exhibited the best in vitro potency of the antibiotics tested against P. aeruginosa, including isolates that were resistant to piperacillin/tazobactam, cefepime, ceftazidime, doripenem, meropenem, ciprofloxacin, levofloxacin, amikacin, and tobramycin. Ceftolozane/tazobactam has the potential to become a useful addition to the limited armamentarium of drugs that can be used to treat this problem pathogen.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Harald Seifert, Barbara Körber-Irrgang, Michael Kresken,